Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Aykut BahçeciSemra PaydaşNaziye AkFerhat FerhatogluPınar Mualla SaipGülşah SeydaoğluMehmet BiliciMelih ŞimşekSalim Başol TekinZüleyha ÇalikuşuSinan YavuzAhmet Bilgehan ŞahinErdem CubukcuTürkkan EvrenselSerkan DegirmenciogluAtike Gökçen DemirayPerran Fulden YumukÖzkan AlanDuygu İlke ÇikmanFuat Hulusi DemirelliOsman KöstekAli GökyerMutlu DoğanÖznur BalBurcu ÇakarErhan GökmenDeniz YamaçTaner KorkmazAltay AliyevÖzge KeskinSemiha UrvayMahmut BüyükşimşekCemile KaradenizBirol YildizHavva Yeşil ÇinkirHacer DemirIsmail BeypinarCengiz KaraçinKadir EserMeltem BaykaraSaadettin KılıçkapKerem OkuturGülcan BulutAli AlkanErkan ArpaciKezban Nur PilanciAtakan DemirDeniz IşikNilgün YildirimPublished in: Cancer investigation (2021)
The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.